Welcome to our dedicated page for Oaktree Acquisition III Life Sciences Unit news (Ticker: OACCU), a resource for investors and traders seeking the latest updates and insights on Oaktree Acquisition III Life Sciences Unit stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oaktree Acquisition III Life Sciences Unit's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oaktree Acquisition III Life Sciences Unit's position in the market.
Oaktree Acquisition Corp. III Life Sciences announced that starting December 16, 2024, holders of units from its initial public offering can separately trade Class A ordinary shares and warrants. Units will continue trading on Nasdaq as 'OACCU', while separated Class A shares and warrants will trade under 'OACC' and 'OACCW' respectively.
To separate units, holders must contact Continental Stock Transfer & Trust Company. Only whole warrants will trade, with no fractional warrants issued. The initial offering was underwritten by Jefferies , Citigroup Global Markets Inc., and UBS Investment Bank as joint book-running managers. The SEC declared the registration statement effective on October 23, 2024.
Oaktree Acquisition Corp. III Life Sciences has announced the pricing of its initial public offering (IPO) of 17,500,000 units at $10.00 per unit, totaling $175 million. The units will trade on Nasdaq under OACCU starting October 24, 2024. Each unit includes one Class A ordinary share and one-fifth of a redeemable warrant. Whole warrants allow holders to purchase shares at $11.50 each. The company granted underwriters a 45-day option to purchase up to 2,625,000 additional units. Jefferies, Citigroup, and UBS Securities are serving as joint book-running managers.
FAQ
What is the current stock price of Oaktree Acquisition III Life Sciences Unit (OACCU)?
